5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.

Title5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.
Publication TypeJournal Article
Year of Publication2011
AuthorsBolaños-Meade J, Smith DB, Gore SD, McDevitt MA, Luznik L, Fuchs EJ, Jones RJ
JournalBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Volume17
Issue5
Pagination754-8
Date Published2011 May
Abstract

Relapse after allogeneic blood or marrow transplantation carries a very poor prognosis. Current strategies for management that include donor lymphocyte infusions (DLIs) and salvage chemotherapies are usually toxic and ineffective. Here we report the outcome of 10 patients with myeloid malignancies that received 5-azacytidine after a failed allogeneic bone marrow transplant. Of the 10 patients, 6 achieved a complete remission, 1 had stable disease, and 3 progressed after a median of 6 cycles administered. Only 1 patient has died (of disease progression), and no flares of graft-versus-host disease (GVHD) were observed with 5-azacytidine. As of latest follow-up, the median overall survival (OS) for the group was 422.5 days (127-1411). These results further suggest that 5-azacytidine is an active agent after failing an allogeneic bone marrow transplant, and prospective studies are warranted.

DOI10.1097/BRS.0b013e3181e7d675
Alternate JournalBiol. Blood Marrow Transplant.